Express News | Astria Therapeutics Announces Initiation of Phase 1a Trial of Star-0310, a Potential Best-in-Class Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis
Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis
Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Cuts Target Price to $22
Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32
Express News | Astria Therapeutics Inc : Jefferies Raises Target Price to $29 From $27
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
